These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

243 related items for PubMed ID: 2719742

  • 1. Cardiovascular effects of the new cardiotonic agent 1,2-dihydro-6-methyl-2-oxo-5-(imidazo[1,2-a]pyridin-6-yl)-3-pyridine carbonitrile hydrochloride monohydrate. 2nd communication: studies in dogs.
    Ohhara H, Ogawa T, Takeda M, Katoh H, Daiku Y, Igarashi T.
    Arzneimittelforschung; 1989 Jan; 39(1):38-45. PubMed ID: 2719742
    [Abstract] [Full Text] [Related]

  • 2. Cardiovascular effects of the new cardiotonic agent 1,2-dihydro-6-methyl-2-oxo-5-(imidazo[1,2-a]pyridin-6-yl)-3-pyridine carbonitrile hydrochloride monohydrate. 1st communication: studies on isolated guinea pig cardiac muscles.
    Ogawa T, Ohhara H, Tsunoda H, Kuroki J, Shoji T.
    Arzneimittelforschung; 1989 Jan; 39(1):33-7. PubMed ID: 2566308
    [Abstract] [Full Text] [Related]

  • 3. Effects of the new cardiotonic phosphodiesterase inhibitor 1,2-dihydro-5- imidazo[1,2-a]pyridin-6-yl-6-methyl-2-oxo-3-pyridine-carbonitrile hydrochloride monohydrate on aortic input impedance.
    Kubota T, Itaya R, Todaka K, Sugimachi M, Sunagawa K, Takeshita A.
    Arzneimittelforschung; 1991 Dec; 41(12):1211-5. PubMed ID: 1815518
    [Abstract] [Full Text] [Related]

  • 4. Cardiovascular pharmacology of 6-[4-(4'-pyridyl)aminophenyl]-4,5-dihydro-3(2H)-pyridazinone hydrochloride, a novel and potent cardiotonic agent with vasodilator properties.
    Narimatsu A, Kitada Y, Satoh N, Suzuki R, Okushima H.
    Arzneimittelforschung; 1987 Apr; 37(4):398-406. PubMed ID: 3606694
    [Abstract] [Full Text] [Related]

  • 5. Cardiovascular effects of (2RS,3SR)- 2-aminomethyl-2,3,7,8-tetrahydro-2,3,5,8,8-pentamethyl-6H-furo- [2,3-e]indol-7-one hydrochloride (UK-1745), a novel cardiotonic agent with vasodilatory and antiarrhythmic properties.
    Uchida Y, Kawada M, Sawanobori K, Sonoki H, Inoue K, Mizuno K, Itou T, Tabunoki Y, Tsukamoto M, Ohashi Y, Kyotani Y, Shimizu N, Fujii M, Nakamura M.
    Arzneimittelforschung; 1998 Mar; 48(3):219-31. PubMed ID: 9553677
    [Abstract] [Full Text] [Related]

  • 6. Cardiovascular properties of a new cardiotonic agent: MDL 17,043 (1.3-dihydro-4-methyl-5-[4-(methylthio)-benzoyl]-2H-imidazol-2-one).
    Dage RC, Roebel LE, Hsieh CP, Weiner DL, Woodward JK.
    J Cardiovasc Pharmacol; 1982 Mar; 4(3):500-8. PubMed ID: 6177949
    [Abstract] [Full Text] [Related]

  • 7. Cardiovascular profile of RWJ 29009, a new potassium channel activator, in anesthetized and conscious dogs.
    Damiano BP, Giardino EC, Haertlein BJ, Stump GL, Mitchell JA, Falotico R.
    J Cardiovasc Pharmacol; 1994 Feb; 23(2):300-10. PubMed ID: 7511761
    [Abstract] [Full Text] [Related]

  • 8. Pharmacological studies with the alpha 2-adrenoceptor antagonist midaglizole. Part I: Respiratory and cardiovascular systems.
    Hirohashi M, Takasuna K, Yamashita N, Tamura K.
    Arzneimittelforschung; 1991 Jan; 41(1):9-18. PubMed ID: 1675573
    [Abstract] [Full Text] [Related]

  • 9. Systemic, pulmonary and coronary haemodynamic actions of the novel dopamine receptor agonist in awake pigs at rest and during treadmill exercise Z1046.
    Duncker DJ, Haitsma DB, van der Geest IE, Stubenitsky R, van Meegen JR, Man in't Veld AJ, Verdouw PD.
    Br J Pharmacol; 1997 Mar; 120(6):1101-13. PubMed ID: 9134223
    [Abstract] [Full Text] [Related]

  • 10. Cardiovascular properties of a new cardiotonic agent, MDL 19205.
    Dage RC, Roebel LE, Hsieh CP, Woodward JK.
    J Cardiovasc Pharmacol; 1984 Mar; 6(1):35-42. PubMed ID: 6199609
    [Abstract] [Full Text] [Related]

  • 11. Zatebradine, a specific bradycardic agent, alters the hemodynamic and left ventricular mechanical actions of levosimendan, a new myofilament calcium sensitizer, in conscious dogs.
    Pagel PS, Harkin CP, Hettrick DA, Warltier DC.
    J Pharmacol Exp Ther; 1995 Oct; 275(1):127-35. PubMed ID: 7562540
    [Abstract] [Full Text] [Related]

  • 12. [Effects of the new cardiotonic agent loprinone hydrochloride (E-1020) on left ventricular diameter in normal and experimental heart failure dogs and its action potential characteristics in isolated guinea pig cardiac muscles and sinus nodes].
    Ohhara H, Sawada K, Ogawa T, Takeda M, Igarashi T.
    Nihon Yakurigaku Zasshi; 1992 Jun; 99(6):421-33. PubMed ID: 1398339
    [Abstract] [Full Text] [Related]

  • 13. Pharmacology of LY175326: a potent cardiotonic agent with vasodilator activities.
    Hayes JS, Pollock GD, Wilson H, Bowling N, Robertson DW.
    J Pharmacol Exp Ther; 1985 May; 233(2):318-26. PubMed ID: 3999023
    [Abstract] [Full Text] [Related]

  • 14. The acute effect of a new positive inotropic agent (AR-L 115 BS) on cardiac hemodynamics and contractility in patients with severe chronic congestive heart failure.
    Hauf GF, Bubenheimer P, Roskamm H.
    Arzneimittelforschung; 1981 May; 31(1a):253-6. PubMed ID: 7195235
    [Abstract] [Full Text] [Related]

  • 15. Hemodynamic response and effects on myocardial energetics of 3-cyano-2-morpholino-5-(pyrid-4-yl)pyridine (AWD 122-14) in anesthetized minipigs.
    Rohde E, Wiesner B, Muschick P.
    Pharmazie; 1993 Sep; 48(9):690-4. PubMed ID: 8234405
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Effect of MCI-154, a cardiotonic agent, on regional contractile function and myocardial oxygen consumption in the presence and absence of coronary artery stenosis in dogs.
    Abe Y, Kitada Y, Narimatsu A.
    J Pharmacol Exp Ther; 1993 May; 265(2):819-25. PubMed ID: 8496827
    [Abstract] [Full Text] [Related]

  • 18. Effects of toborinone on myocardial oxygen consumption in pacing-induced heart failure dogs.
    Itoh S, Mori T, Fujiki H, Tominaga M.
    Arzneimittelforschung; 1996 Dec; 46(12):1105-9. PubMed ID: 9006782
    [Abstract] [Full Text] [Related]

  • 19. Cardiovascular effects of the new positive inotropic agent denopamine with special reference to species difference and the effect on failing heart.
    Ikeo T, Nagao T, Murata S, Yabana H, Sato M, Nakajima H.
    Arzneimittelforschung; 1986 Jul; 36(7):1063-8. PubMed ID: 3768073
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.